Enadenotucirev

Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers.^[1]

Enadenotucirev
Virus classification
(unranked):	Virus
Realm:	Varidnaviria
Kingdom:	Bamfordvirae
Phylum:	Preplasmiviricota
Class:	Pharingeaviricetes
Order:	Rowavirales
Family:	Adenoviridae
Genus:	Mastadenovirus
Species:	Human mastadenovirus B

It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1.^[2]

Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents.^{[citation needed]}

The T-SIGn vectors at clinical study stage are:^{[citation needed]}

• NG-350A: This vector contains two transgenes expressing the heavy and light chains for a secreted CD40 agonist monoclonal antibody.
• NG-641: This vector contains four transgenes expressing secreted Interferon alpha, the chemokines CXCL9, CXCL10 and an anti-FAP/anti-CD3 bispecific T-cell activator

In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer.^[3]

Clinical trials

Two clinical trials have been completed with enadenotucirev. The EVOLVE study ^[4] and the MOA study.^[5]

As of June 2019^[update], there are two active phase 1 trials: OCTAVE (in ovarian cancer)^[6] and SPICE (in multiple solid tumor indications) ^[7]

Of the T-SIGn viruses, NG-350A has an ongoing clinical study.^[8]

See also

• Oncolytic adenovirus
  • Oncolytic adenovirus#Directed Evolution